摘要
Abstract
Objective:To investigate the clinical efficacy of metformin combined with orlistat in obese patients with polycystic ovary syndrome(PCOS)and insulin resistance.Methods:A total of 150 obese PCOS patients with insulin resistance were randomly divided into control group and research group,with 75 cases in each group.The control group was given basic treatment such as metformin and ethinylestradiol cycloproterone,and the research group was treated with basic treatment combined with orlistat.After 3 months of treatment,the differences in anthropometric indicators,glycolipid metabolism indicators and sex hormone levels between the two groups were compared.Results:After 3 months of treatment,compared with the control group,the body weight,body mass index(BMI),waist-to-hip ratio(WHR),body fat percentage,fasting plasma glucose(FPG),2 h postprandial plasma glucose(2hPG),fasting insulin(FINS),glycosylated hemoglobin(HbA1c),and homeostasis model assessment-IR(HOMA-IR)of the research group were significantly decreased(P＜0.05);and the triglyceride,total cholesterol,low density lipoprotein cholesterol in the research group were also significantly decreased(P＜0.05),while high density lipoprotein cholesterol was significantly increased(P＜0.05);the levels of luteinizing hormone(LH),estradiol,testosterone,prolactin and LH/follicle stimulating hormone(FSH)were greatly decreased(P＜0.05),while there was no significant difference in FSH(P＞0.05).Conclusion:Metformin combined with orlistat in the treatment of obese PCOS with insulin resistance could significantly improve the glucose and lipid metabolism,reduce weight and insulin resistance and improve sexual hormone disorder.关键词
多囊卵巢综合征/肥胖/胰岛素抵抗/二甲双胍/奥利司他/性激素/糖代谢/脂代谢Key words
polycystic ovarian syndrome/obesity/insulin resistance/metformin/ollistat/sex hormone/glucose metabolism/lipid metabolism分类
医药卫生
